News
DGAP-News: DEMIRE Deutsche Mittelstand Real Estate AG: Annual General Meeting approves all TOPs with clear majority
DGAP-News: init innovation in traffic systems SE: Shareholders’ meeting approves the Managing Board’s report and strategy
Form 8.3 - The Vanguard Group, Inc.: Meggitt plc
Eaton Named to 100 Best Corporate Citizens List for 15th Consecutive Year by 3BL Media
Power management company Eaton (NYSE:ETN) today announced that it has been named one of the 100 Best Corporate Citizens for the 15th consecutive year by 3BL Media. The ranking recognizes
EQS-News: Mobile TeleSystems PJSC: MTS Announces Q1 2022 Results
PAO Severstal: Severstal obtains permission to maintain its GDR program
Form 8.3 - The Vanguard Group, Inc.: ContourGlobal plc
Form 8.3 - The Vanguard Group, Inc.: HomeServe plc
The Vanguard Group, Inc.: GXO Logistics, Inc.
Form 8.3 - The Vanguard Group, Inc.: Avast plc
DGAP-News: PNE AG: Annual General Meeting approves dividend
Fuller, Smith & Turner PLC: HOL-Holding(s) in Company
Chelverton UK Dividend Trust plc: Net Asset Value(s)
Additional details regarding second interim dividend
SThree: DSH-Director/PDMR Shareholding*
Rights and Issues Investment Trust PLC: Net Asset Value(s)
REPLY – Digital Experience Is Recognised as No. 1 Internet Agency and Company Group for the Fourth Year in a Row by BVDW
As done in the previous three years, the Bundesverband Digitale Wirtschaft (BVDW) honours Reply – Digital Experience once again as the top company in their ranking of Internet Agencies for 2022.
EQS-News: PJSC Mechel : MECHEL REPORTS RECEIVING PERMISSION TO CONTINUE CIRCULATION OF ITS ADRS OUTSIDE RUSSIA
Sberbank: Sber informs on the conversion of depository receipts into ordinary shares
Lysogene Provides Clinical Update on AAVance Phase 2/3 Clinical Trial with Gene Therapy LYS-SAF302 for the Treatment of MPS IIIA at the 25th Annual ASGCT Meeting
Regulatory News:
Lysogene (FR0013233475 – LYS), a phase 3 gene therapy platform company targeting central nervous system (CNS) diseases, provided updated clinical data from the ongoing AAVance